Supplementary Figures 1-3, Supplementary Tables 1-2, Supplementary References from Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Supplementary Fig 1. Overall survival by HER2 mRNA percentile Supplementary Fig 2. Patient disposition and biomarker availability in the EMILIA trial. Supplementary Fig 3. Potential mechanism by which T-DM1 may bypass a common resistance pathway in HER2-positive cancer cells Supplementary Table 1. REMARK2 Checklist. Supplementary Table 2. Selected Patient Demographic and Baseline Characteristics by Treatment Arm in Evaluable and Nonevaluable Patients.